As previously reported, Bernstein analyst William Pickering earlier upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform with a $572 price target The stock in midday trading is down 1% to $460.43. Bernstein named Vertex a top biotech pick for 2026. The sector entered 2026 “mounting an impressive comeback, finally emerging from three years in the wilderness,” the analyst tells investors in a research note. The firm attributes the group’s 36% gain in 2025 to lower interest rates, increasing acquisition activity, and lower perceived policy risks. Bernstein expects 2026 “to be a big year for the sector,” with continued deal-making and a better initial public offering market.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Bernstein
- Vertex Advances Suzetrigine Phase 3 Trial in Diabetic Nerve Pain, Signaling a Broader Growth Story
- Sionna Therapeutics price target raised to $58 from $50 at BTIG
- Vertex Pharmaceuticals assumed with a Buy at UBS
- Wolfe upgrades Vertex Pharmaceuticals, says ‘may be due for a rebound’